Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2025-09-25 Director's Dealing
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification regarding a transaction on company shares by a member of the Supervisory Board (Robert Florczykowski). This is a classic insider dealing notification, which falls under the category of Director's Dealing.
2025-09-25 Polish
Załącznik do raportu
Director's Dealing Classification · 100% confidence The document is a formal notification under Article 19(1) of the Market Abuse Regulation (MAR) regarding a transaction by a person discharging managerial responsibilities (PDMR). It details the name of the director (Charles Kunsch), his position (Member of the Supervisory Board), the issuer (Captor Therapeutics S.A.), and specific details of the share subscription transaction (price, volume, and date). This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-09-25 English
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification regarding a transaction on company shares by a member of the Supervisory Board (Charles Kunsch). It explicitly references Article 19 of the MAR (Market Abuse Regulation), which is the standard regulatory framework for reporting insider dealings. Since it details a specific transaction by a director/insider, it falls under the 'Director's Dealing' category.
2025-09-25 Polish
Załącznik do raportu
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically a member of the Supervisory Board (Krzysztof Samotij) of Captor Therapeutics S.A. It explicitly references Article 19(1) of the Market Abuse Regulation (MAR). This type of disclosure, where a director or executive reports their personal share transactions, is classified as a Director's Dealing.
2025-09-25 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a short notification from the company regarding a transaction on company shares by a member of the Supervisory Board (Krzysztof Samotij). This is a classic disclosure of insider dealing or director's transactions as required by the Market Abuse Regulation (MAR). Therefore, it falls under the 'Director's Dealing' category.
2025-09-25 Polish
Załącznik do raportu
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically the Chief Financial Officer (Dyrektor ds. Finansowych) of Captor Therapeutics. It explicitly references Article 19(1) of the Market Abuse Regulation (MAR) and provides details on the acquisition of company shares (ISIN: PLCPTRT00014). This fits the definition of a Director's Dealing (DIRS) report.
2025-09-25 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.